132 related articles for article (PubMed ID: 2164086)
1. BY 1023/SK&F 96022 INN pantoprazole, a novel gastric proton pump inhibitor, potently inhibits acid secretion but lacks relevant cytochrome P450 interactions.
Kromer W; Postius S; Riedel R; Simon WA; Hanauer G; Brand U; Gönne S; Parsons ME
J Pharmacol Exp Ther; 1990 Jul; 254(1):129-35. PubMed ID: 2164086
[TBL] [Abstract][Full Text] [Related]
2. In vivo cytochrome P 450 interactions of the newly developed H+/K(+)-ATPase inhibitor pantoprazole (BY 1023/SK&F 96022) compared to other antiulcer drugs.
Hanauer G; Graf U; Meissner T
Methods Find Exp Clin Pharmacol; 1991; 13(1):63-7. PubMed ID: 1651432
[TBL] [Abstract][Full Text] [Related]
3. The H+, K(+)-ATPase inhibitor pantoprazole (BY1023/SK&F96022) interacts less with cytochrome P450 than omeprazole and lansoprazole.
Simon WA; Büdingen C; Fahr S; Kinder B; Koske M
Biochem Pharmacol; 1991 Jul; 42(2):347-55. PubMed ID: 1650212
[TBL] [Abstract][Full Text] [Related]
4. By 1023/SK&F 96022: biochemistry of a novel (H+ + K+)-ATPase inhibitor.
Simon WA; Keeling DJ; Laing SM; Fallowfield C; Taylor AG
Biochem Pharmacol; 1990 Jun; 39(11):1799-806. PubMed ID: 2160820
[TBL] [Abstract][Full Text] [Related]
5. Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo.
Kwon D; Chae JB; Park CW; Kim YS; Lee SM; Kim EJ; Huh IH; Kim DY; Cho KD
Arzneimittelforschung; 2001; 51(3):204-13. PubMed ID: 11304936
[TBL] [Abstract][Full Text] [Related]
6. Lack of pantoprazole drug interactions in man.
Steinijans VW; Huber R; Hartmann M; Zech K; Bliesath H; Wurst W; Radtke HW
Int J Clin Pharmacol Ther; 1994 Aug; 32(8):385-99. PubMed ID: 7981922
[TBL] [Abstract][Full Text] [Related]
7. Proton pump inhibitors: new drugs and indications.
Mears JM; Kaplan B
Am Fam Physician; 1996 Jan; 53(1):285-92. PubMed ID: 8546054
[TBL] [Abstract][Full Text] [Related]
8. Correlation between acid secretion and proton pump activity during inhibition by the proton pump inhibitors omeprazole and pantoprazole.
Nishioka K; Nagao T; Urushidani T
Biochem Pharmacol; 1999 Oct; 58(8):1349-59. PubMed ID: 10487539
[TBL] [Abstract][Full Text] [Related]
9. Differences in binding properties of two proton pump inhibitors on the gastric H+,K+-ATPase in vivo.
Shin JM; Sachs G
Biochem Pharmacol; 2004 Dec; 68(11):2117-27. PubMed ID: 15498502
[TBL] [Abstract][Full Text] [Related]
10. The sulphoxide moiety of substituted benzimidazoles is essential for inhibition of parietal cell K+/H+-ATPase.
Beil W; Eltze M; Heintze K; Klemm K; Riedel R; Schudt C; Sewing KF; Simon A
Br J Pharmacol; 1986 Jun; 88(2):389-95. PubMed ID: 3015311
[TBL] [Abstract][Full Text] [Related]
11. [Discovery and development of the proton pump inhibitor].
Igata H; Okabe S
Nihon Rinsho; 1992 Jan; 50(1):11-7. PubMed ID: 1311779
[TBL] [Abstract][Full Text] [Related]
12. Effects of pantoprazole on xenobiotic metabolizing enzymes in rat liver microsomes: a comparison with other proton pump inhibitors.
Masubuchi N; Hakusui H; Okazaki O
Drug Metab Dispos; 1997 May; 25(5):584-9. PubMed ID: 9152597
[TBL] [Abstract][Full Text] [Related]
13. Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats.
Satoh H; Inatomi N; Nagaya H; Inada I; Nohara A; Nakamura N; Maki Y
J Pharmacol Exp Ther; 1989 Feb; 248(2):806-15. PubMed ID: 2537418
[TBL] [Abstract][Full Text] [Related]
14. Sulfide and sulfoxide derivatives of substituted benzimidazoles inhibit acid formation in isolated gastric glands by different mechanisms.
Fryklund J; Wallmark B
J Pharmacol Exp Ther; 1986 Jan; 236(1):248-53. PubMed ID: 3001289
[TBL] [Abstract][Full Text] [Related]
15. (H+,K+)-ATPase inhibiting 2-[(2-pyridylmethyl)sulfinyl]benzimidazoles. 4. A novel series of dimethoxypyridyl-substituted inhibitors with enhanced selectivity. The selection of pantoprazole as a clinical candidate.
Kohl B; Sturm E; Senn-Bilfinger J; Simon WA; Krüger U; Schaefer H; Rainer G; Figala V; Klemm K
J Med Chem; 1992 Mar; 35(6):1049-57. PubMed ID: 1313110
[TBL] [Abstract][Full Text] [Related]
16. Lack of pantoprazole drug interactions in man: an updated review.
Steinijans VW; Huber R; Hartmann M; Zech K; Bliesath H; Wurst W; Radtke HW
Int J Clin Pharmacol Ther; 1996 May; 34(1 Suppl):S31-50. PubMed ID: 8793602
[TBL] [Abstract][Full Text] [Related]
17. Pantoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion.
Dammann HG; Burkhardt F
Eur J Gastroenterol Hepatol; 1999 Nov; 11(11):1277-82. PubMed ID: 10563540
[TBL] [Abstract][Full Text] [Related]
18. Studies on (H(+)-K+)-ATPase inhibitors of gastric acid secretion. Prodrugs of 2-[(2-pyridinylmethyl)sulfinyl]benzimidazole proton-pump inhibitors.
Sih JC; Im WB; Robert A; Graber DR; Blakeman DP
J Med Chem; 1991 Mar; 34(3):1049-62. PubMed ID: 1848293
[TBL] [Abstract][Full Text] [Related]
19. Similarities and differences in the properties of substituted benzimidazoles: a comparison between pantoprazole and related compounds.
Kromer W
Digestion; 1995; 56(6):443-54. PubMed ID: 8536813
[TBL] [Abstract][Full Text] [Related]
20. The novel proton pump inhibitor pantoprazole elevates intragastric pH for a prolonged period when administered under conditions of stimulated gastric acid secretion in the gastric fistula dog.
Postius S; Bräuer U; Kromer W
Life Sci; 1991; 49(14):1047-52. PubMed ID: 1832475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
